{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:33Z","timestamp":1793191773249,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Emicizumab is approved for routine prophylaxis, but limited data exist investigating the relationship between bleeds and exercise in people with haemophilia A (PwHA) receiving emicizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the relationship between physical activity and bleeding outcomes in Japanese PwHA receiving emicizumab prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicentre, observational study was conducted in Japanese PwHA initiating emicizumab between November 2019 and October 2021. Physical activity and bleeding events were reported using an electronic patient\u2010reported outcomes application, while activity intensity was collected by a wearable activity tracker worn over five 8\u2010day monitoring periods. Data on safety were recorded by investigators using electronic case report forms. Quality of life data were also collected and will be reported in a separate publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 129 participants enrolled. Median age was 32 years (range 0\u201373), and 83.7% of participants had severe HA. Overall, 73 participants performed 968 exercise events, with 18.8% and 6.0% of events classified as moderate and high risk, respectively. Two (0.2%) exercise events were associated with bleeding: one basketball (moderate risk) and one fishing (low risk). In total, 137 adverse events (AEs) were reported in 62 participants. No serious AEs were emicizumab\u2010related. The mean annualised treated bleed rate was 1.9 and 51 (39.5%) participants experienced zero bleeds during the study period (97 weeks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that PwHA receiving emicizumab prophylaxis can participate in a wide range of physical activities with minimal bleeding risk, which supports their access to the health benefits of exercise. Emicizumab remains well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70070","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:44:20Z","timestamp":1750301060000},"page":"703-712","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab"],"prefix":"10.1111","volume":"31","author":[{"given":"Kagehiro","family":"Amano","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6959-6346","authenticated-orcid":false,"given":"Teruhisa","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine\/Hemophilia Treatment Center Hiroshima University Hospital  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Hematology Hyogo Medical University  Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1126-1498","authenticated-orcid":false,"given":"Azusa","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Blood Coagulation Ogikubo Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiai","family":"Nagae","sequence":"additional","affiliation":[{"name":"Department of Pediatrics St. Marianna University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[{"name":"Center for Translational Research\/Division of Advanced Medicine Promotion Institute of Medical Science, University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine Nagoya University Hospital  Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1632-5315","authenticated-orcid":false,"given":"Mika","family":"Kawano","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Shimura","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Sugao","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Hattori","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-2194","authenticated-orcid":false,"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University  Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01456.x"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286292"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000565"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15444"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07386.x"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-683169"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15676"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14828"},{"key":"e_1_2_12_12_1","unstructured":"Genentech \u00a0Inc.HEMLIBRA\u00ae(Emicizumab\u2010Kxwh) Injection for Subcutaneous Use Prescribing Information(2024) accessed January 2025 https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102415"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14363"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13985"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01507.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14800"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.01.007"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12474"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03679-8"},{"key":"e_1_2_12_23_1","unstructured":"ActiGraph CentrePoint\u00aeInsight Watch accessed January 2025 https:\/\/theactigraph.com\/cpiw."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005768-200009001-00009"},{"key":"e_1_2_12_25_1","volume-title":"Playing It Safe: Bleeding Disorders, Sport and Exercise","author":"Anderson A.","year":"2017"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.2019.030692"},{"key":"e_1_2_12_27_1","unstructured":"Japan: Ministry of Health LaW Physical Activity and Exercise Guide for Health Promotion(2023) accessed January 2025 https:\/\/www.mhlw.go.jp\/content\/001194020.pdf."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1123\/jpah.2013-0464"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-024-05902-y"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13773"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.47391\/JPMA.EGY-S4-10"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1275337"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0072"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13215"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718784834"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02433.x"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001311"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021832"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T20:35:22Z","timestamp":1773002122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/hae.70070"],"URL":"https:\/\/doi.org\/10.1111\/hae.70070","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"2024-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}